Log In
BCIQ
Print this Print this
 

ABO-101 (formerly ABX-102, ABX-B)

  Manage Alerts
Collapse Summary General Information
Company Abeona Therapeutics Inc.
DescriptionAdeno-associated viral serotype 9 (AAV9) vector that delivers the N-acetylglucosaminidase alpha (NAGLU) gene
Molecular Target N-acetylglucosaminidase alpha (NAGLU)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPhase I/II
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo type B syndrome)
Regulatory Designation U.S. - Orphan Drug (Treat mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo type B syndrome))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$40.9M

0

$9.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/18/2015

$40.9M

0

$9.0M

Get a free BioCentury trial today